Gemcitabine (GEM) — Cisplatin (COOP) — Vinorelbine (VNR) combination in advanced non-small-cell lung cancer (NSCLC). A phase II randomized study
P. Comella, G. Comella(Tumour Institute of Tuscany), G.P. lanniello, G.P. Nicolella(Radiation Oncology Institute), Franco Vito Piantedosi, N. Panza, E Micillo(Medical Center Hospital), R Cioffi(Medical Center Hospital), Luigi Maiorino(Medical Center Hospital), Carmen Pacilio(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), J. Perchard, Maria Vittoria, Michèle Natale(Medical Center Hospital), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Luigi Manzione, V. Lorusso(Gastroenterology Hospital "Saverio de Bellis"), G. Frasci(Radiation Oncology Institute)
Cited by 1
Related Papers
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group
|Journal of Clinical Oncology|2000|177
Lapatinib in breast cancer
|Annals of Oncology|2007|129
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108